Sign inJoin waitlistJoin the waitlist

Anne Tsao

VP, Faculty & Academic Affairs, CAO Office · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2001–2004
Internal Medicine
Indiana University School of Medicine
1998–1999
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
1994–1998

Research

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase…
Journal of Clinical Oncology · 2019 · 1,075 citations
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
The Lancet · 2021 · 999 citations
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic…
The Lancet Oncology · 2016 · 930 citations

John Heymach
51 papers
George Blumenschein
31 papers
Don Gibbons
28 papers
Jianjun Zhang
28 papers
David Rice
27 papers
Frank Fossella
27 papers
Reza Mehran
27 papers
BS
Boris Sepesi
25 papers
Daniel Gomez
22 papers
JL
Joanna Lee
22 papers · 7 as a resident
Stephen Swisher
22 papers
WH
Waun Hong
22 papers

Grants

UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAPS) UG1
National Cancer Institute · UG1
Contact PI · $11.1M · University of Tx Md Anderson Can Ctr
2019–2032
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
National Cancer Institute · U10
Contact PI · $1.3M · University of Tx Md Anderson Can Ctr
2014–2020

Clinical trials

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
Principal investigator · Active not recruiting · Phase 1
M.D. Anderson Cancer Center
2019–2027
Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
Principal investigator · Completed · Phase 2
SWOG Cancer Research Network
2019–2025
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2018–2026
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2017–2027